RPS announces proposal to become a Royal College – BOPA and the UK PPL Board

BOPA are an ex-officio member of the UK PPL Board.  Please see the boards statement below on the RPS announcement of a proposal to become a Royal College:

UK Pharmacy Professional Leadership Advisory Board Statement

12 September 2024

“The UK Pharmacy Professional Leadership Advisory Board was set up to support and steer the transition to a sustainable and effective structure of pharmacy professional leadership across the UK over a period of 3-5 years.

“We support the Royal Pharmaceutical Society in its proposals for a new constitution and governance framework as a positive and enabling step on a journey towards the Board’s ambition.

“Successfully realising this ambition in full over time will depend on sustaining inclusive and close collaboration and an ongoing commitment to transparency.

“The Board will continue to work closely with the professional leadership bodies and specialist professional groups in co-creating the next steps of the journey to help facilitate a positive future for pharmacists, pharmacy technicians and wider pharmacy teams. We encourage RPS members to engage positively with the consultation as we all develop pharmacy professional leadership in the interests of patients, the public and the professions.”

For further information: Independent UK Pharmacy Professional Leadership Advisory Board to strengthen collaboration | Join the Conversation (scwcsu.nhs.uk)

Contact email: [email protected]

 

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article